Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes
Long-term dupilumab therapy provided durable disease control and excellent safety. Personalized dosing-interval extension maintained efficacy and reduced treatment burden, supporting its potential role in optimizing long-term management of CRSwNP, especially in patients with troublesome side effects.
Authors
- Mohammed Zghaebi (ORCID: https://orcid.org/0000-0002-7636-2601)
- Fana Alem Kidane
- Tina Bartosik (ORCID: https://orcid.org/0000-0002-6326-7402)
- Aldine Tu (ORCID: https://orcid.org/0009-0008-0278-2778)
- Linda N. Liu (ORCID: https://orcid.org/0000-0002-4220-1076)
- Victoria Stanek
- Julia Eckl-Dorna
- Sven Schneider (ORCID: https://orcid.org/0000-0002-7631-3746)
- Nicholas James Campion (ORCID: https://orcid.org/0000-0003-3345-9486)
- Christina Morgenstern
- Florian C Fally
- Katarina Gangl
- Noah F Melamed
- Minghao Pan
- Karina Berbalk
- Dioni-Pinelopi Petsiou
Institutions
- Vienna General Hospital (AT)
Publication Details
- Journal
- International Forum of Allergy & Rhinology
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1002/alr.70125
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00